Drug Trial Radar · NCT05467475
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood
Last checked: Nov 20, 2026Latest source record: Jan 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Oct 18, 2022
Primary completion
Jan 23, 2023
Study completion Jan 23, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 1819479 in plasma.
Conditions
- Healthy
Interventions
BI 1819479Drug
BI 1819479
EsomeprazoleDrug
Esomeprazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to 31 days.
- Maximum measured concentration of the analyte in plasma (Cmax)Time frame: Up to 31 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.